Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 584

1.

Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update.

Stoffer MA, Schoels MM, Smolen JS, Aletaha D, Breedveld FC, Burmester G, Bykerk V, Dougados M, Emery P, Haraoui B, Gomez-Reino J, Kvien TK, Nash P, Navarro-Compán V, Scholte-Voshaar M, van Vollenhoven R, van der Heijde D, Stamm TA.

Ann Rheum Dis. 2016 Jan;75(1):16-22. doi: 10.1136/annrheumdis-2015-207526. Epub 2015 May 19. Review. Erratum in: Ann Rheum Dis. 2016 May;75(5):946.

2.

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.

Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compán MV, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Haraoui B, Kouloumas M, Landewe R, Martin-Mola E, Nash P, Ostergaard M, Östör A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, van der Heijde D.

Ann Rheum Dis. 2016 Jan;75(1):3-15. doi: 10.1136/annrheumdis-2015-207524. Epub 2015 May 12. Review.

3.

Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension.

Keystone EC, Breedveld FC, van der Heijde D, Landewé R, Florentinus S, Arulmani U, Liu S, Kupper H, Kavanaugh A.

J Rheumatol. 2014 Jan;41(1):5-14. doi: 10.3899/jrheum.130543. Epub 2013 Nov 15.

4.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.

Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D.

Ann Rheum Dis. 2014 Mar;73(3):492-509. doi: 10.1136/annrheumdis-2013-204573. Epub 2013 Oct 25.

5.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012.

Furst DE, Keystone EC, So AK, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Rubbert-Roth A, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop KL.

Ann Rheum Dis. 2013 Apr;72 Suppl 2:ii2-34. doi: 10.1136/annrheumdis-2013-203348. No abstract available.

PMID:
23532441
6.

Advances in targeted therapies XIV.

Breedveld FC, Kalden JR, Smolen JS.

Ann Rheum Dis. 2013 Apr;72 Suppl 2:ii1. doi: 10.1136/annrheumdis-2012-202416. No abstract available.

PMID:
23532438
7.

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.

Smolen JS, Schoels MM, Nishimoto N, Breedveld FC, Burmester GR, Dougados M, Emery P, Ferraccioli G, Gabay C, Gibofsky A, Gomez-Reino JJ, Jones G, Kvien TK, Murakami M, Betteridge N, Bingham CO 3rd, Bykerk V, Choy EH, Combe B, Cutolo M, Graninger W, Lanas A, Martin-Mola E, Montecucco C, Ostergaard M, Pavelka K, Rubbert-Roth A, Sattar N, Scholte-Voshaar M, Tanaka Y, Trauner M, Valentini G, Winthrop KL, de Wit M, van der Heijde D.

Ann Rheum Dis. 2013 Apr;72(4):482-92. doi: 10.1136/annrheumdis-2012-202469. Epub 2012 Nov 21.

8.

Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement.

Schoels MM, van der Heijde D, Breedveld FC, Burmester GR, Dougados M, Emery P, Ferraccioli G, Gabay C, Gibofsky A, Gomez-Reino JJ, Jones G, Kvien TK, Murakami M, Nishimoto N, Smolen JS.

Ann Rheum Dis. 2013 Apr;72(4):583-9. doi: 10.1136/annrheumdis-2012-202470. Epub 2012 Nov 10. Review. Erratum in: Ann Rheum Dis. 2013 Jun;72(6):1110. Murikama, Miho M [corrected to Murakami, Miho].

9.

Advances in targeted therapies XIII.

Breedveld FC, Kalden JR, Smolen JS.

Ann Rheum Dis. 2012 Apr;71 Suppl 2:i1. doi: 10.1136/annrheumdis-2011-201013. No abstract available.

PMID:
22460135
10.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011.

Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop K.

Ann Rheum Dis. 2012 Apr;71 Suppl 2:i2-45. doi: 10.1136/annrheumdis-2011-201036. No abstract available.

PMID:
22460137
11.

European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies.

Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, FitzGerald O, Aletaha D, Balint P, Boumpas D, Braun J, Breedveld FC, Burmester G, Cañete JD, de Wit M, Dagfinrud H, de Vlam K, Dougados M, Helliwell P, Kavanaugh A, Kvien TK, Landewé R, Luger T, Maccarone M, McGonagle D, McHugh N, McInnes IB, Ritchlin C, Sieper J, Tak PP, Valesini G, Vencovsky J, Winthrop KL, Zink A, Emery P; European League Against Rheumatism.

Ann Rheum Dis. 2012 Jan;71(1):4-12. doi: 10.1136/annrheumdis-2011-200350. Epub 2011 Sep 27.

12.

Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire.

Haraoui B, Smolen JS, Aletaha D, Breedveld FC, Burmester G, Codreanu C, Da Silva JP, de Wit M, Dougados M, Durez P, Emery P, Fonseca JE, Gibofsky A, Gomez-Reino J, Graninger W, Hamuryudan V, Jannaut Peña MJ, Kalden J, Kvien TK, Laurindo I, Martin-Mola E, Montecucco C, Santos Moreno P, Pavelka K, Poor G, Cardiel MH, Stanislawska-Biernat E, Takeuchi T, van der Heijde D; Treat to Target Taskforce.

Ann Rheum Dis. 2011 Nov;70(11):1999-2002. doi: 10.1136/ard.2011.154179. Epub 2011 Jul 29.

13.

Understanding emerging treatment paradigms in rheumatoid arthritis.

Breedveld FC, Combe B.

Arthritis Res Ther. 2011 May 25;13 Suppl 1:S3. doi: 10.1186/1478-6354-13-S1-S3. Review.

14.

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.

Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dörner T, Ferraccioli G, Gottenberg JE, Isaacs J, Kvien TK, Mariette X, Martin-Mola E, Pavelka K, Tak PP, van der Heijde D, van Vollenhoven RF, Emery P; Rituximab Consensus Expert Committee.

Ann Rheum Dis. 2011 Jun;70(6):909-20. doi: 10.1136/ard.2010.144998. Epub 2011 Mar 6.

15.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010.

Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, Winthrop K.

Ann Rheum Dis. 2011 Mar;70 Suppl 1:i2-36. doi: 10.1136/ard.2010.146852. No abstract available.

PMID:
21339216
16.

Advances in targeted therapies XII. Preface.

Breedveld FC, Kalden JR, Smolen JS.

Ann Rheum Dis. 2011 Mar;70 Suppl 1:i1. doi: 10.1136/ard.2010.141044. No abstract available.

PMID:
21339210
17.

Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis.

Smolen JS, Boers M, Abadie EC, Breedveld FC, Emery P, Bardin T, Goel N, Ethgen DJ, Avouac BP, Durez P, Flamion B, Laslop A, Miossec P, Reiter S, Reginster JY; Task Force of the Group for the Respect of Ethics and Excellence in Science.

Rheumatology (Oxford). 2011 Oct;50(10):1732-6. doi: 10.1093/rheumatology/keq413. Epub 2011 Jan 17. No abstract available.

18.

Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA.

Smolen JS, Boers M, Abadie EC, Breedveld FC, Emery P, Bardin T, Goel N, Ethgen DJ, Avouac BP, Dere WH, Durez P, Matucci-Cerinic M, Flamion B, Laslop A, Lekkerkerker FJ, Miossec P, Mitlak BH, Ormarsdóttir S, Paolozzi L, Rao R, Reiter S, Tsouderos Y, Reginster JY; Group for Respect of Ethics and Excellence in Science (GREES).

Curr Med Res Opin. 2011 Feb;27(2):315-25. doi: 10.1185/03007995.2010.542135. Epub 2010 Dec 9.

PMID:
21142618
19.

Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER.

van der Heijde D, Breedveld FC, Kavanaugh A, Keystone EC, Landewé R, Patra K, Pangan AL.

J Rheumatol. 2010 Nov;37(11):2237-46. doi: 10.3899/jrheum.100208. Epub 2010 Oct 1.

20.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.

Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, van Vollenhoven R, Winthrop KL, Wong J, Zink A, van der Heijde D.

Ann Rheum Dis. 2010 Jun;69(6):964-75. doi: 10.1136/ard.2009.126532. Epub 2010 May 5. Review. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk